A Study of Adebrelimab in Combination with Chemo with or Without Bevacizumab Neoadjuvant Therapy for Resectable NSCLC
A Randomized Phase II Study of Adebrelimab in Combination with Chemotherapy with or Without Bevacizumab Neoadjuvant Therapy for Resectable Non-Squamous Non-Small Cell Lung Cancer
The First Affiliated Hospital of Guangzhou Medical University
60 participants
Sep 24, 2024
INTERVENTIONAL
Conditions
Summary
This is a prospective, multicenter, randomized, uncontrolled Phase II study to assess the efficacy and safety of adebrelimab in combination with chemotherapy with or without bevacizumab for the treatment of resectable Stage II-IIIB (T3N2) NSQ-NSCLC and to explore biomarkers associated with efficacy.
Eligibility
Inclusion Criteria6
- Resectable NSQ NSCLC
- Age 18-65 years
- male or female
- ECOG 0-1
- Subjects have not received surgery, chemotherapy, radiotherapy and biological treatment of treatment-naive non-squamous non-small cell lung cancer
- Subjects must have adequate pulmonary function for the intended pneumonectomy;
Exclusion Criteria5
- SCLC or SQ NSCLC
- previously used anti-PD1, anti-PDL1, anti-CTLA4 antibodies, etc.
- patients who have previously used anti-angiogenic drugs;
- allergic to any component of the study drug or chemotherapy drugs
- patients with any severe and or uncontrolled disease
Interventions
adebrelimab
bevacizumab
paclitaxel or albuminotaxol or docetaxel combined with platinum, pemetrexed combined with platinum. Platinums include carboplatin, cisplatin and nedaplatin.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06775275